This years 2026 ASCO Gastrointestinal Cancers Symposium was packed with practice-shaping data across colorectal and upper ...

Onvansertib added to FOLFIRI/bev first-line standard of care regimen showed dose-dependent improvement in overall response rates and durability ...

Onvansertib combined with FOLFIRI and Avastin shows dose-dependent improvements in tumor response and disease control for RAS ...

Cohort 3 analysis from the BREAKWATER study shows objective response rate of 64% with BRAFTOVI plus cetuximab and FOLFIRI compared to 39% with standard-of-care treatment FOLFIRI with or without ...

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported positive initial ...

Cardiff Oncology (NASDAQ:CRDF) outlined a management transition and provided an updated clinical data readout for onvansertib during a company conference call focused on its ongoing Phase II CRDF-004 ...

Yakult Honsha has patented a method for predicting the effectiveness of FOLFOX or FOLFIRI regimens in treating stage IV colorectal cancer. By measuring copy number gains in specific chromosome regions ...

Pfizer Inc. (NYSE: PFE) today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating BRAFTOVI ® (encorafenib) in combination with cetuximab ...